Cefazolin dosing for surgical prophylaxis in morbidly obese patients

Surgical Infections

Volumn 13, Issue 1, 2012, Pages 33-37

  Ho, Vanessa P ^a   Nicolau, David P ^b   Dakin, Gregory F ^a   Pomp, Alfons ^a   Rich, Barrie S ^a   Towe, Christopher W ^a   Barie, Philip S ^a,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b HARTFORD HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; ELECTIVE SURGERY; FEMALE; HUMAN; INFECTION PREVENTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURGICAL INFECTION; SURGICAL SITE INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BODY MASS INDEX; CEFAZOLIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBESITY, MORBID; SURGICAL PROCEDURES, ELECTIVE; SURGICAL WOUND INFECTION;

EID: 84858123206     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2010.097     Document Type: Article

References (32)

1. Wang Y, Beydoun MA. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: A systematic review and meta-regression analysis. Epidemiol Rev 2007:6-28. (Pubitemid 47229643)
2. Caballero B. The global epidemic of obesity: An overview. Epidemiol Rev 2007;29:1-5. (Pubitemid 47229648)
3. Obesity: Preventing and managing the global epidemic: Report of a WHO Consultation Series WHO Technical Report Series 894. Geneva. World Health Organization. 2000.
4. Livingston EH. Procedure incidence and in-hospital complication rates of bariatric surgery in the United States. Am J Surg 2004;188:105-110. (Pubitemid 38916726)
5. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg 2009;19:1605-1611.
6. Dindo D, Muller MK, Weber M, et al. Obesity in general elective surgery. Lancet 2003;361:2032-2035. (Pubitemid 36695045)
7. Lillenfeld DE, Vlahov D, Tenney JH, et al. Obesity and diabetes as risk factors for postoperative wound infections after cardiac surgery. Am J Infect Control 1988;16:3-6. (Pubitemid 18069281)
8. Pikarsky AJ, Saida Y, Yamaguchi T, et al. Is obesity a high-risk factor for laparoscopic colorectal surgery? Surg Endosc 2002;16:855-858. (Pubitemid 34429452)
9. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacother 2007;27:1081-1091.
10. Bearden DT, Rodvold KA. Dosage adjustments for antibac-terials in obese patients: Applying clinical pharmacokinetics. Clin Pharmacokinet 2000;38:415-426. (Pubitemid 30265261)
11. Cheymol G. Effects of obesity on pharmacokinetics: Implications for drug therapy. Clin Pharmacokinet 2000;39:215-231.
12. Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1982;7:108-124. (Pubitemid 12070477)
13. Pieracci FM, Barie PS, Pomp A. Critical care of the bariatric patient. Crit Care Med 2006;34:1796-1804. (Pubitemid 43810065)
14. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-327.
15. Traynor AM, Nafziger AN, Bertino JS Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995;39:545-548.
16. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
17. Ohashi K, Tsunoo M, Tsuneoka K. Pharmacokinetics and protein binding of cefazolin and cephalothin in patients with cirrhosis. J Antimicrob Chemother 1986;17:347-351. (Pubitemid 16162915)
18. Dudley MN, Nightingale CH, Drezner AD, et al. Comparative penetration of cefonicid and cefazolin into the atrial appendage and pericardial fluid of patients undergoing open-heart surgery. Antimicrob Agents Chemother 1984;26:347-350. (Pubitemid 14006022)
19. Hospital-Acquired Conditions 2010. Available at www.cms.hhs.gov/ HospitalAcqCond/06-Hospital-Acquired-Conditions.asp Accessed March 15, 2010.
20. Forse RA, Karam B, MacLean LD, et al. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989; 106:750-757. (Pubitemid 19255086)
21. Pories WJ, Van Rij AM, Burlingham BT, et al. Prophylactic cefazolin in gastric bypass surgery. Surgery 1981;90:426-432. (Pubitemid 11047258)
22. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: A randomized study of outcomes, quality of life, and costs. Ann Surg 2001;234:279-289.
23. Nguyen NT, Dakin G, Needleman B, et al. Effect of staple height on gastrojejunostomy during laparoscopic gastric bypass: A multicenter prospective randomized trial. Surg Obes Relat Dis;6:477-482.
24. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232:515-529.
25. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: Do we achieve therapeutic levels? Surgery 2004;136:738-747. (Pubitemid 39311298)
26. Clinical and Laboratory Standards Institute. Document M100-S20 (2010): Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet. Available at www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/Cephalos porinandAztreonamBreakpointRevisionFactSheet/Cephalos porinAztreonamBreakpointFactSheet.pdf Accessed October 5, 2010.
27. Roberts JA, Lipman J. Continuous infusion of beta-lactams in the ICU-Best way to hit the target. Crit Care Med 2008;36:1663-1664. (Pubitemid 351620604)
28. Roberts JA, Paratz J, Paratz E, et al. Continuous infusion of beta-lactam antibiotics in severe infections: A review of its role. Int J Antimicrob Agents 2007;30:11-18. (Pubitemid 46874893)
29. Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-289.
30. Van Zanten ARH, Oudijk M, Nohlmans-Paulssen MKE, et al. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics/pharmaco- dynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007;63:100-109. (Pubitemid 44902883)
31. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007;13:598-606. (Pubitemid 47357464)
32. Alexander JW, Rahn R, Goodman HR. Prevention of surgical site infections by an infusion of topical antibiotics in morbidly obese patients. Surg Infect 2009;10:53-57.